Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial

Amber Tong

When Kaleido Biosciences unveiled results from a multi-center, open label, controlled clinical study testing its microbiome product in Covid-19 patients back in March, the biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial

Amber Tong

Sign up to read this article for free.

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food or drug? FDA blasts Flag­ship-backed mi­cro­bio­me play­er’s ‘non-IND’ Covid-19 tri­al

Amber Tong

Sign up to read this article for free.

more like this

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront